Overview
Attruby is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cardiomyopathy (disorder of the heart muscle) caused by wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is used to reduce heart-related death and hospitalization. Attruby is also known by its drug name, acoramidis.

Attruby is a transthyretin stabilizer, meaning it binds to transthyretin (TTR), a protein involved in amyloid formation. By stabilizing TTR, Attruby prevents the breakdown of the protein into monomers, which is the first step in the formation of amyloid deposits that contribute to disease progression.

How do I take it?
Prescribing information states that Attruby is taken orally as tablets, generally twice daily. Tablets should be swallowed whole and not cut, crushed, or chewed. It can be taken with or without food. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Attruby include diarrhea and upper abdominal pain. 

Rare but serious side effects may include an increase in serum creatinine levels and a decrease in estimated glomerular filtration rate (eGFR), which are indicators of kidney function. These changes typically occur within the first month of treatment and stabilize over time. They are reversible if treatment is discontinued.

For more information about this treatment, visit:

Label: Attruby — Acoramidis Hydrochloride Tablet, Film Coated — DailyMed